Isis Pharmaceuticals Inc. last week delivered the coup de grace to ISIS 2105, an antisense oligonucleotide being developed as a surgical adjuvant therapy for patients with genital warts. The announcement came as no surprise to the market, which had largely written off the compound after earlier Phase II trials as a primary therapy and as a